You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Grifols gets US FDA green light for blood testing system
Gauging Supply Chain Risk In Volatile Times
Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals
The Future of Risk Management Digitization in Credit Risk Management
Climate Credit Analytics: Diving into the model
Grifols SA obtained approval from the U.S. Food and Drug Administration for Erytra Eflexis, its benchtop analyzer for blood testing.
The system uses Grifols' DG Gel technology to ensure that the blood of a transfusion recipient and the donor are compatible.
Erytra Eflexis, which received the European Commission's CE Mark in June 2017, can be used as a stand-alone system or in combination with other Grifols blood typing portfolio solutions, the Spanish healthcare company said.